Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

GemsBot Jun. 21 at 11:54 AM

5 of 11 $HON $IBM $JNJ Dark green arrows indicate strong buy signals, while dark red arrows indicate strong sell signals. Lighter colored arrows are confirmation signals or signals to add, for large portfolios that use multiple entry points … see 6/11

0 · Reply

BioRich Jun. 21 at 1:03 AM

$CLSD Feeling very fortunate to get in on this gem before it goes on a triple digit run. Locked and loaded on this low float. Hope you are too! Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital $XBI $JNJ $PFE $GILD

1 · Reply

Ro_Patel Jun. 21 at 12:05 AM

Now: President Trump & his associates have repeatedly criticized companies’ moves to offshore much drug making, particularly to Ireland. “We can’t be beholden & rely upon foreign countries for fundamental things that we need” Commerce Secretary Lutnick said on April 13 Then: But the tax incentives in President Trump’s 2017 tax & spending package helped generate this problem in the 1st place — a problem that would continue under the bill under consideration Republicans tend to blame Ireland’s lower corporate tax rate for the proliferation of corporate tax avoidance, but the real incentive comes from this obscure corner of the tax code. It offers a far-lower 10.5% tax rate for global profits if a global firm moves the profits from its IP offshore. The tax rate for domestic profits, in contrast, is 21% The tax break was created by Republicans Unsurprisingly, America’s imports of pharmaceuticals soaring to $250B in 2024, way up from $110B back in 2016 $XLV $PFE $JNJ $LLY - $AAPL

2 · Reply

m00nerTRADESz3 Jun. 20 at 6:54 PM

$JNJ

0 · Reply

DIMOHolder Jun. 20 at 2:22 PM

$JNJ price predictions for next week guys ???

0 · Reply

Suite510 Jun. 19 at 11:53 PM

$JNJ $KVUE $SPX Unless Asbestos left Earth, flush the toilet on JNJ 😂🤷‍♂️ “JNJ recent legal challenges, specifically the $8 million jury award related to talcum powder products, have raised concerns about potential impacts on its financial narrative” duh 🙄

0 · Reply

Rage_Against_The_Machine Jun. 19 at 12:12 PM

$JNJ expands its orthopedics leadership with new VOLT plating systems for wrist and shoulder fractures - targeting the growing $10B+ trauma market. Launching during peak osteoporosis season with redesigned implants could boost MedTech's 36% revenue share. Surgical efficiency claims look substantive but need real-world adoption. https://www.prnewswire.com/news-releases/johnson--johnson-launches-volt-wrist-and-proximal-humerus-plating-systems-in-the-us-302485762.html

0 · Reply

DonCorleone77 Jun. 19 at 2:51 AM

$JNJ Johnson & Johnson to pay $8M in Massachusetts mesothelioma talc lawsuit A Suffolk County jury has awarded $8M in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson & Johnson's talcum powder products. The jury found the company liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talcum powder products caused Paluzzi's terminal cancer. J&J ceased production and sale of all products containing talc in the United States in 2020. Ms. Paluzzi was diagnosed with mesothelioma in 2021.

0 · Reply

Quantumup Jun. 18 at 8:44 PM

William Blair🏁 $CTNM Outperform-$23.26 and said, "We are initiating coverage of Contineum Therapeutics with an Outperform rating and fair value of $23.26 per share." $BMY $JNJ $TGTX RHHBY $AXSM LLY PFE ABBV GSK TAK William Blair went on to say:

0 · Reply

sister Jun. 18 at 7:56 PM

$MRNA be fine back at 29.19 . . . was $170.47 last May and could be again on Sharp Reversal. $PFE $JNJ

1 · Reply

If I Could Only Buy 2 Dividend Stocks: June's Top Picks For Global Diversification

AAPL BLK MO

Jun 18, 2025, 6:43 PM EDT - 2 days ago

Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit

Jun 17, 2025, 3:38 PM EDT - 3 days ago

Johnson & Johnson CEO: “We're in the Golden Era of Medical Innovation”

Jun 17, 2025, 10:00 AM EDT - 4 days ago

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan

ABBV AMGN MRK PFE

Jun 17, 2025, 8:00 AM EDT - 4 days ago

I'm Buying Dividend Aristocrats At Bargain Basement Prices

BSX KO MDT PEP

Jun 15, 2025, 3:15 AM EDT - 6 days ago

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Jun 14, 2025, 8:06 AM EDT - 7 days ago

Johnson & Johnson CEO: 'We're in the Golden Era of Medical Innovation'

Jun 13, 2025, 11:00 AM EDT - 7 days ago

Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

Jun 12, 2025, 11:00 AM EDT - 8 days ago

New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

Jun 11, 2025, 5:54 PM EDT - 9 days ago

Johnson & Johnson (JNJ) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 11, 2025, 8:05 AM EDT - 10 days ago

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

Jun 10, 2025, 4:51 PM EDT - 10 days ago

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

Jun 6, 2025, 4:08 PM EDT - 14 days ago

Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?

ABBV ABT LLY UNH XLV

Jun 3, 2025, 10:45 AM EDT - 17 days ago

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity

Jun 3, 2025, 10:45 AM EDT - 17 days ago

Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients

$Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma$

Jun 3, 2025, 10:45 AM EDT - 17 days ago

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

Jun 3, 2025, 10:45 AM EDT - 17 days ago

Johnson & Johnson's AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care

Jun 3, 2025, 8:00 AM EDT - 18 days ago

Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC

Jun 2, 2025, 4:00 PM EDT - 18 days ago

June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035

ARCC CNQ CVS CVX KHC OMC PEP

Jun 2, 2025, 11:00 AM EDT - 18 days ago

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

LLY ABVX

Jun 2, 2025, 7:41 AM EDT - 19 days ago

'No more tears': Author Gardiner Harris on J&J's controversies over the years

May 30, 2025, 10:07 AM EDT - 22 days ago

Johnson & Johnson: Relative Stability In A Wild 2025 Stock Market

May 30, 2025, 8:04 AM EDT - 22 days ago

J&J CEO Joaquin Duato on cancer treatments, M&A outlook and 'most favored nation' policy

May 28, 2025, 4:43 PM EDT - 23 days ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 28, 2025, 2:31 PM EDT - 23 days ago

Johnson & Johnson (JNJ) Presents at the Bernstein's 41st Annual Strategic Decisions Conference (Transcript)

May 27, 2025, 8:30 AM EDT - 25 days ago

Johnson & Johnson: Dividend King On Sale Yielding Over 3% And Undervalued

May 27, 2025, 5:39 AM EDT - 25 days ago

Johnson & Johnson: Raising My Price Target Amid Stable EPS Growth

May 26, 2025, 7:30 AM EDT - 26 days ago

No Rolex For Me - I'm Buying Dividends That Pay For Life

GD LOW MCD MDT TXN

May 23, 2025, 8:00 AM EDT - 4 weeks ago

FDA Panel Reiterates the Cancer Risks of Talc

May 21, 2025, 4:40 PM EDT - 4 weeks ago

Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference

May 21, 2025, 9:00 AM EDT - 4 weeks ago

Forget About Dividend Yield, Do This Instead

AAPL BAC C COP CVX D DUK

May 20, 2025, 6:21 PM EDT - 4 weeks ago

U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

May 20, 2025, 3:10 PM EDT - 4 weeks ago

Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference

May 20, 2025, 12:24 PM EDT - 4 weeks ago

Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts

May 19, 2025, 3:25 PM EDT - 4 weeks ago

Moody's U.S. Debt Downgrade: Stocks Poised To Benefit

AAL AAPL CCL CUK F GM GOOG

May 18, 2025, 4:32 PM EDT - 4 weeks ago

Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson's Biosense Webster Medical Technology Unit

May 15, 2025, 5:48 PM EDT - 5 weeks ago

Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails

May 14, 2025, 8:00 PM EDT - 5 weeks ago

Jim Cramer talks good companies getting pummeled by rising interest rates

ABBV BMY CL GM PEP PG

May 14, 2025, 4:40 PM EDT - 5 weeks ago

Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 13, 2025, 2:51 PM EDT - 5 weeks ago

Johnson & Johnson (JNJ) BofA Securities 2025 Healthcare Conference Transcript

May 13, 2025, 11:18 AM EDT - 5 weeks ago

Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.

LLY PFE ABBV

May 12, 2025, 6:25 PM EDT - 5 weeks ago

50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy

FDX GS JWN KO LLY LOW MS

May 12, 2025, 3:54 PM EDT - 5 weeks ago

Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know

ABBV GSK LLY MRK NVO NVS PFE

May 12, 2025, 3:35 PM EDT - 5 weeks ago

Johnson & Johnson: For Those Who Want Some Immunity Against Tariff Changes

May 12, 2025, 2:39 PM EDT - 5 weeks ago

10 stocks for a high-tariff world

BNS CMS EPD IDA KMB OBDC PEP

May 12, 2025, 1:14 PM EDT - 5 weeks ago

Drugmakers are spared worst-case drug pricing scenario for now

ABBV LLY MRK PFE

May 12, 2025, 12:36 PM EDT - 5 weeks ago

Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

ABBV AMGN AZN GILD GSK LLY MRK

May 12, 2025, 12:30 PM EDT - 5 weeks ago

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

ABBV AMGN BIIB BMY GILD LLY MRK

May 12, 2025, 11:24 AM EDT - 5 weeks ago

Trump says executive order will slash the cost of prescription drugs

ABBV LLY MRK PFE

May 12, 2025, 10:47 AM EDT - 5 weeks ago

Trump Announces Executive Order to Lower Drug Prices

LLY PFE MRK

GemsBot Jun. 21 at 11:54 AM

0 · Reply

BioRich Jun. 21 at 1:03 AM

1 · Reply

Ro_Patel Jun. 21 at 12:05 AM

2 · Reply

m00nerTRADESz3 Jun. 20 at 6:54 PM

$JNJ

0 · Reply

DIMOHolder Jun. 20 at 2:22 PM

$JNJ price predictions for next week guys ???

0 · Reply

Suite510 Jun. 19 at 11:53 PM

0 · Reply

Rage_Against_The_Machine Jun. 19 at 12:12 PM

0 · Reply

DonCorleone77 Jun. 19 at 2:51 AM

0 · Reply

Quantumup Jun. 18 at 8:44 PM

0 · Reply

sister Jun. 18 at 7:56 PM

$MRNA be fine back at 29.19 . . . was $170.47 last May and could be again on Sharp Reversal. $PFE $JNJ

1 · Reply

PumpUpDumpDown Jun. 18 at 6:02 PM

$JNJ this evil company your time has come 🇮🇱

0 · Reply

StockAutoPro Jun. 18 at 3:01 PM

$JNJ: Holding at $152.38, minor dip. Buy near $151, target $160 on diversified pharma strength.

1 · Reply

sister Jun. 18 at 1:49 PM

$MRNA righte after they shake you out, they reverse for 29.19 coming. You betcha. $PFE $JNJ

2 · Reply

DIMOHolder Jun. 18 at 1:09 PM

$JNJ is anyone buying calls here after this massive selloff ?? Any price predictions for next week guys ??

0 · Reply

Hotresearchsgoldenage Jun. 18 at 11:45 AM

$JNJ … Urgn cures bladder cancer at close to 80 percent success rate. Cole’s ship in July @ 21,500 per treatment .

0 · Reply

StockAutoPro Jun. 18 at 2:39 AM

$JNJ: Holding at $152.38, minor dip. Buy near $151, target $160 on diversified pharma strength.

0 · Reply

Ned_Nosurname Jun. 17 at 11:09 PM

$LYEL $JNJ $GILD https://www.oncologypipeline.com/apexonco/lyell-takes-jj-and-gilead

3 · Reply

Suite510 Jun. 17 at 8:44 PM

$JNJ $KVUE lol 😂

0 · Reply

PumpUpDumpDown Jun. 17 at 8:01 PM

$JNJ This company isn’t blessed by god 🇮🇱

0 · Reply

BioRich Jun. 17 at 7:56 PM

$TLSA Ready for an after hours run. Alzheimers Drug in Phase 2 Presenting tomorrow. Big time player at dirt cheap share price. Definitely worth a look. $TSLA (Tesla) folks, worth a look. Likely better returns than Tesla (no bash on Tesla, simple evaluation of the massive potential in this promising Bio). $PFE $JNJ $LLY

1 · Reply

AltcoinsPumpAndDump2024 Jun. 17 at 7:27 PM

$JNJ in 2 trading days it went down $5 manipulated pos.

0 · Reply

sister Jun. 17 at 6:38 PM

$MRNA wasn't this $170.87 last May with Healthcare Analysts calling for significant 2025 recovery? $PFE $JNJ

1 · Reply

Market Cap	362.67B
Revenue (ttm)	88.82B
Net Income (ttm)	14.07B
EPS (ttm)	N/A
PE Ratio	15.16
Forward PE	14.22
Profit Margin	15.84%
Debt to Equity Ratio	0.49

Volume	22,605,400
Avg Vol	8,522,652
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	9%
Beta	0.42
Analysts	Sell
Price Target	$169.83